[Adriablastin (doxorubicin) in the combined chemotherapy of patients with disseminated forms of breast cancer].

Antibiotiki Pub Date : 1984-06-01
E K Voznyĭ, N S Besova, T V Kurkina, Iu B Al'tshtuller
{"title":"[Adriablastin (doxorubicin) in the combined chemotherapy of patients with disseminated forms of breast cancer].","authors":"E K Voznyĭ,&nbsp;N S Besova,&nbsp;T V Kurkina,&nbsp;Iu B Al'tshtuller","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A total of 119 patients were treated for disseminated cancer of the mammary gland according to two schemes with the use of adriablastin. It was shown that in the treatment of metastases into the bones adriablastin was the drug of choice. The treatment of such patients with it may be effective. The analgetic action of the drug was noted in 80 per cent of the patients. The roentgenologically observed objective effect of the drug was provided by the doses higher than 300 mg and the treatment period of not less than 4 months. In the treatment of patients with metastases of other localization the schemes with the use of adriablastin had no advantage over the Cooper scheme.</p>","PeriodicalId":7959,"journal":{"name":"Antibiotiki","volume":"29 6","pages":"463-8"},"PeriodicalIF":0.0000,"publicationDate":"1984-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotiki","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

A total of 119 patients were treated for disseminated cancer of the mammary gland according to two schemes with the use of adriablastin. It was shown that in the treatment of metastases into the bones adriablastin was the drug of choice. The treatment of such patients with it may be effective. The analgetic action of the drug was noted in 80 per cent of the patients. The roentgenologically observed objective effect of the drug was provided by the doses higher than 300 mg and the treatment period of not less than 4 months. In the treatment of patients with metastases of other localization the schemes with the use of adriablastin had no advantage over the Cooper scheme.

[阿达伐星(阿霉素)在弥散性乳腺癌患者联合化疗中的应用]。
根据两种方案,对119例乳腺播散性癌患者使用阿不拉素进行治疗。研究表明,在骨转移的治疗中,阿不拉素是首选药物。用它治疗这类病人可能是有效的。在80%的病人身上发现了这种药物的止痛作用。x线学观察到的客观效果是剂量大于300mg且疗程不少于4个月。在治疗其他部位转移的患者时,使用阿不伐他汀的方案与Cooper方案相比没有优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信